Search results
Results from the WOW.Com Content Network
If taking Paxlovid, some side effects, according to the treatment’s fact sheet, could include allergic reactions, liver problems, nausea, high blood pressure, altered sense of taste and ...
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. [11] [13] These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects and toxicity. [8]
The most common side effect in people with COVID‑19 is nausea. [13] Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. [24] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [25]
A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study ...
Nirmatrelvir/ritonavir is under investigation, so its side effects have yet to be fully evaluated and may not be completely known. [19] Other side effects of nirmatrelvir/ritonavir may include hypersensitivity reactions, liver toxicity, and development of HIV drug resistance in people with uncontrolled or undiagnosed HIV infection.
[44] [45] As of May 2020 several antiviral drugs were under investigation for COVID-19, though none had been shown to be clearly effective on mortality in published randomized controlled trials. [44] As of February 2021, in the European Union, the use of dexamethasone and remdesivir were authorized. [46]
COVID-19: Shionogi: 3C-like protease inhibitor Entecavir: HIV NRTI 2005 Etravirine (Intelence) [8] HIV NNRTI 2008 Famciclovir: Herpes Zoster: Guanosine analogue 1994 Fomivirsen: AIDS Anti-sense oligonucleotide: Anti-sense FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA ...